Gene Expression Profiling for Rheumatoid Arthritis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately differentiate between rheumatoid arthritis (RA) and spondyloarthritis (SpA) in early stages, leading to inappropriate treatment and potential long-term morbidity due to their distinct disease mechanisms and requirements.
Innovation Solution
Measuring the expression levels of a specific set of genes in synovial tissue or blood samples, which are differentially expressed in RA and SpA, allowing for discrimination between the two conditions based on reference values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then diagnosis can be performed, but differentiation between RA and SpA in early stages is inaccurate
Solution Approach 1:
The patent segments the diagnostic approach by dividing it into multiple independent gene expression measurements (20-30 different genes) rather than relying on a single marker. This segmentation allows for more precise differentiation between RA and SpA by analyzing the combined expression patterns of multiple genes, thereby improving both measurement precision and differentiation reliability in early disease stages
Solution Approach 2:
The patent changes the diagnostic parameter from traditional single-marker methods to a multi-gene expression profile. By measuring expression levels of 20-30 genes and analyzing their combined patterns, the method transforms the diagnostic approach to achieve higher accuracy in differentiating RA from SpA, directly addressing the contradiction between measurement precision and differentiation reliability
2Loss of time
If early diagnosis is performed, then treatment can be initiated sooner, but current methods lack the precision to differentiate diseases accurately
Solution Approach 1:
The patent applies preliminary action by establishing a comprehensive multi-gene expression profile early in the disease process. By measuring 20-30 gene expressions at the earliest possible stage and comparing against established reference patterns, the method enables accurate differentiation before disease progression complicates the clinical picture, thus reducing diagnosis time without sacrificing precision
Solution Approach 2:
The patent substitutes traditional mechanical/diagnostic methods with a molecular biology-based gene expression analysis system. This replacement enables early and accurate differentiation by detecting molecular signatures before clinical symptoms fully manifest, simultaneously achieving early diagnosis and high measurement precision
3Ease of manufacture
If traditional diagnostic methods are used, then treatment can be provided, but inappropriate treatment may result due to misdiagnosis
Solution Approach 1:
The patent implements feedback by using gene expression profiles to guide treatment decisions. The multi-gene analysis provides feedback on the actual disease type (RA vs. SpA), enabling clinicians to select appropriate treatments tailored to the specific diagnosis, thereby ensuring treatment appropriateness while maintaining ease of implementation through standardized molecular testing
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The invention provides a method for typing samples for rheumatoid arthritis and spondyloarthritis. Typing can be performed in order to discriminate between rheumatoid arthritis and spondyloarthritis in early disease. The invention further provides sets of genes to be used in a method of the invention and a nucleotide microarray and use thereof.